SPRY vs. LEGN, TGTX, GRFS, LNTH, TLX, NUVL, AXSM, AKRO, PCVX, and ADMA
Should you be buying ARS Pharmaceuticals stock or one of its competitors? The main competitors of ARS Pharmaceuticals include Legend Biotech (LEGN), TG Therapeutics (TGTX), Grifols (GRFS), Lantheus (LNTH), Telix Pharmaceuticals (TLX), Nuvalent (NUVL), Axsome Therapeutics (AXSM), Akero Therapeutics (AKRO), Vaxcyte (PCVX), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry.
ARS Pharmaceuticals vs. Its Competitors
ARS Pharmaceuticals (NASDAQ:SPRY) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.
ARS Pharmaceuticals presently has a consensus price target of $31.00, suggesting a potential upside of 85.07%. Legend Biotech has a consensus price target of $74.18, suggesting a potential upside of 106.58%. Given Legend Biotech's higher possible upside, analysts plainly believe Legend Biotech is more favorable than ARS Pharmaceuticals.
ARS Pharmaceuticals has a net margin of -16.11% compared to Legend Biotech's net margin of -29.95%. ARS Pharmaceuticals' return on equity of -6.94% beat Legend Biotech's return on equity.
68.2% of ARS Pharmaceuticals shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 33.5% of ARS Pharmaceuticals shares are owned by company insiders. Comparatively, 0.0% of Legend Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, ARS Pharmaceuticals had 8 more articles in the media than Legend Biotech. MarketBeat recorded 14 mentions for ARS Pharmaceuticals and 6 mentions for Legend Biotech. Legend Biotech's average media sentiment score of 1.44 beat ARS Pharmaceuticals' score of 0.97 indicating that Legend Biotech is being referred to more favorably in the news media.
ARS Pharmaceuticals has higher earnings, but lower revenue than Legend Biotech. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Legend Biotech, indicating that it is currently the more affordable of the two stocks.
ARS Pharmaceuticals has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500.
Summary
ARS Pharmaceuticals beats Legend Biotech on 11 of the 17 factors compared between the two stocks.
Get ARS Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SPRY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ARS Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:SPRY) was last updated on 7/2/2025 by MarketBeat.com Staff
